loading
Schlusskurs vom Vortag:
$42.38
Offen:
$42.35
24-Stunden-Volumen:
326.23K
Relative Volume:
0.20
Marktkapitalisierung:
$6.73B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-13.92
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+0.33%
1M Leistung:
+6.74%
6M Leistung:
+21.76%
1J Leistung:
-16.61%
1-Tages-Spanne:
Value
$42.17
$42.81
1-Wochen-Bereich:
Value
$41.24
$42.81
52-Wochen-Spanne:
Value
$23.95
$52.34

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
Firmenname
Ionis Pharmaceuticals Inc
Name
Telefon
(760) 931-9200
Name
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Name
Mitarbeiter
927
Name
Twitter
@ionispharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
IONS's Discussions on Twitter

Vergleichen Sie IONS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
42.31 6.68B 705.14M -453.90M -551.29M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.50 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.19 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.06 31.99B 3.81B -644.79M -669.77M -6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-01 Hochstufung Barclays Equal Weight → Overweight
2025-04-07 Eingeleitet H.C. Wainwright Buy
2025-03-31 Eingeleitet Redburn Atlantic Neutral
2024-08-02 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-07-24 Hochstufung Leerink Partners Market Perform → Outperform
2024-07-16 Fortgesetzt Jefferies Buy
2024-06-14 Hochstufung Bernstein Underperform → Mkt Perform
2024-04-10 Hochstufung Wolfe Research Peer Perform → Outperform
2024-01-02 Hochstufung BofA Securities Neutral → Buy
2023-10-23 Hochstufung BofA Securities Underperform → Neutral
2023-09-29 Eingeleitet Raymond James Strong Buy
2023-07-31 Hochstufung Citigroup Neutral → Buy
2023-06-07 Fortgesetzt Piper Sandler Overweight
2023-05-04 Hochstufung Citigroup Sell → Neutral
2023-03-21 Eingeleitet Bernstein Underperform
2022-12-21 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-09-09 Fortgesetzt Morgan Stanley Overweight
2022-07-18 Fortgesetzt Oppenheimer Outperform
2022-03-31 Fortgesetzt Piper Sandler Overweight
2022-03-01 Eingeleitet Citigroup Sell
2022-03-01 Eingeleitet Guggenheim Buy
2022-02-01 Herabstufung BofA Securities Buy → Underperform
2021-12-14 Hochstufung William Blair Mkt Perform → Outperform
2021-05-07 Hochstufung UBS Sell → Neutral
2021-03-01 Hochstufung Barclays Underweight → Equal Weight
2020-12-16 Eingeleitet UBS Sell
2020-12-15 Hochstufung Cowen Market Perform → Outperform
2020-09-14 Fortgesetzt JP Morgan Neutral
2020-09-02 Eingeleitet The Benchmark Company Hold
2020-06-01 Fortgesetzt Oppenheimer Outperform
2020-05-13 Eingeleitet RBC Capital Mkts Outperform
2020-03-05 Eingeleitet Citigroup Buy
2019-12-13 Eingeleitet Oppenheimer Outperform
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-11-07 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-09-10 Hochstufung Bernstein Mkt Perform → Outperform
2018-08-08 Bestätigt Stifel Hold
2018-08-07 Bestätigt Stifel Hold
2018-05-08 Herabstufung Evercore ISI Outperform → In-line
2017-10-06 Fortgesetzt Goldman Sell
2017-08-17 Eingeleitet Evercore ISI Outperform
2017-08-09 Bestätigt Stifel Hold
2017-03-10 Herabstufung Goldman Neutral → Sell
2016-12-28 Bestätigt BMO Capital Markets Outperform
2016-12-27 Bestätigt Leerink Partners Mkt Perform
Alle ansehen

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

pulisher
Jul 23, 2025

Ionis Pharmaceuticals Inc. Stock Analysis and ForecastRemarkably fast returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Is Ionis Pharmaceuticals Inc. a good long term investmentSuperior risk-adjusted returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Ionis Pharmaceuticals Inc. stockRapid portfolio appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Ionis Pharmaceuticals Inc. stock priceHigh-profit trading signals - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Lou Gehrig’s Disease Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corpo - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now - 富途牛牛

Jul 22, 2025
pulisher
Jul 21, 2025

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - GlobeNewswire Inc.

Jul 21, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Ionis HAE drug shows strong results in switch study - Investing.com Australia

Jul 21, 2025
pulisher
Jul 21, 2025

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice - Yahoo Finance

Jul 21, 2025
pulisher
Jul 17, 2025

Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com

Jul 17, 2025
pulisher
Jul 16, 2025

(IONS) Technical Data - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

Ionis Pharmaceuticals to Host Q2 2025 Earnings Webcast on July 30th - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Ionis to hold second quarter 2025 financial results webcast - Business Wire

Jul 16, 2025
pulisher
Jul 16, 2025

Ionis To Hold Second Quarter 2025 Financial Results Webcast - Barchart.com

Jul 16, 2025
pulisher
Jul 15, 2025

Ionis Pharma CEO Monia sells $48,416 in stock By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Ionis Pharmaceuticals CEO Monia Brett Sells 1160 Shares at $41.74 - AInvest

Jul 15, 2025
pulisher
Jul 14, 2025

Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com

Jul 14, 2025
pulisher
Jul 10, 2025

Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT - Insider Monkey

Jul 10, 2025
pulisher
Jul 09, 2025

11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey

Jul 09, 2025
pulisher
Jul 06, 2025

Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com

Jul 06, 2025
pulisher
Jul 06, 2025

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire - MSN

Jul 06, 2025
pulisher
Jul 04, 2025

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? - MSN

Jul 04, 2025
pulisher
Jul 04, 2025

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN

Jul 04, 2025
pulisher
Jul 03, 2025

Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross? - Zacks Investment Research

Jul 03, 2025
pulisher
Jul 03, 2025

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st

Jul 03, 2025
pulisher
Jul 02, 2025

Ionis Pharmaceuticals Surges Amid Promising SMA Treatment Progress - StocksToTrade

Jul 02, 2025
pulisher
Jul 02, 2025

Ionis Pharmaceuticals Advances as Barclays Upgrades Stock - timothysykes.com

Jul 02, 2025
pulisher
Jul 02, 2025

Ionis Pharmaceuticals shares surge 8.89% intraday after Barclays analyst upgrades rating to 'Overweight'. - AInvest

Jul 02, 2025
pulisher
Jul 01, 2025

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know - Nasdaq

Jul 01, 2025
pulisher
Jul 01, 2025

Next Generation RNA Therapeutics Market Set to Witness - openPR.com

Jul 01, 2025
pulisher
Jun 29, 2025

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight (NASDAQ:IONS) - Seeking Alpha

Jun 29, 2025
pulisher
Jun 25, 2025

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results - Business Wire

Jun 25, 2025
pulisher
Jun 23, 2025

First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome. - Yahoo Finance

Jun 23, 2025
pulisher
Jun 20, 2025

The Escalator: Idorsia, Digitas Health, Ionis Pharmaceuticals and more - Medical Marketing and Media

Jun 20, 2025

Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
YANG MICHAEL J.
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
6,010
WENDER JOSEPH H
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
136,835
PARSHALL B LYNNE
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
91,344
HERMAN JOAN E
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
46,086
Hayden Michael R
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
54,298
Diaz Allene M.
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
19,795
BERTHELSEN SPENCER R
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
156,013
Monia Brett P
Chief Executive Officer
Jul 11 '25
Sale
41.74
1,160
48,416
179,820
Hayden Michael R
Director
May 01 '25
Buy
31.86
15,000
477,900
50,219
Birchler Brian
EVP, Corp and Development Ops
Apr 15 '25
Option Exercise
0.00
1,875
0
57,340
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$113.95
price down icon 0.57%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):